GE Healthcare Launches its First “Next-Generation” Sequencing Assay
ALISO VIEJO, Calif.--(BUSINESS WIRE)--
GE Healthcare announced today that Clarient Diagnostic Services, Inc., a
GE Healthcare company, will begin offering a next-generation sequencing
assay focused on solid tumor targets for use in clinical trials. This
assay will empower researchers to perform prospective and retrospective
analysis to better understand which patients will respond to particular
therapies, to help stratify patient populations for ongoing clinical
trials, and to aid early research efforts.
The assay is the first next-generation sequencing assay launched by GE
Healthcare since its acquisition of SeqWright, Inc., a research
laboratory offering nucleic acid sequencing and other genomic services.
The acquisition added complementary genomics capabilities to Clarient,
providing a platform for Clarient to expand its clinical diagnostic
offerings to include next generation sequencing.
Today, pharmaceutical companies are focusing on particular key drivers
of cancer to develop targeted therapies, said Kenneth J. Bloom, MD,
Chief Medical Officer, Clarient Diagnostic Services, Inc. By providing
an assay limited to the most relevant and actionable genes in drug
development today, we hope to further our mission of bringing clarity to
a complex disease and aiding the biopharmaceutical industry in their
clinical research endeavors. Additionally, because genomic sequencing
procedures are important technologies for GE Healthcares medical
diagnostics business, availability of this assay allows us to offer a
substantially wider range of services to the biopharmaceutical,
diagnostic and research industries and eventually to health care
providers and patients.
This new offering will further enable GE Healthcares current
collaborations with pharmaceutical companies focused on biomarker
research. The assay will target the 26 most common oncogenes and tumor
suppressor genes, selected for their implication in prevalent solid
tumor indications such as lung cancer, breast cancer, colon cancer and
melanoma. The assay will be performed at Clarients CLIA-certified
facility, where reflex and adjunct testing can be performed as necessary.
GE Healthcare, through its Clarient business, currently offers a number
of comprehensive clinical and research assays focused on the most common
mutations in solid tumor indications as well as leukemia and lymphomas.
With this offering, GE Healthcare continues to refine its strategy and
focus on the most actionable genes within oncology. Todays announcement
also reinforces the Companys commitment to cancer and reflects its
current integrated portfolio and GE Healthcares $1B R&D investment to
advance oncology solutions by 2016.
When GE Healthcare acquired SeqWright last year, one goal was to add
incremental value to our existing pharmaceutical and biotechnology
partnerships throughout their drug development and companion diagnostic
development efforts, said Carrie Eglinton-Manner, CEO, Clarient.
Availability of this next-generation assay is realization of that goal.
As pharmaceutical companies continue to develop large portfolios of
increasingly targeted drug therapies, the need for fast, accurate and
cost effective sequencing technologies and services to determine the
genetic profile of patient samples becomes vital to clinical trials and
the development of companion diagnostics.
Clarient is a CLIA licensed facility that combines innovative diagnostic
technologies with world class pathology expertise to assess and
characterize cancer. Clarient's mission is to become the leader in
cancer diagnostics by dedicating itself to collaborative relationships
with the healthcare community to translate cancer discovery and research
into better patient care. Clarient was acquired by GE Healthcare in
December of 2010. For more information, visit www.clarientinc.com.
GE Healthcare provides transformational medical technologies and
services to meet the demand for increased access, enhanced quality and
more affordable healthcare around the world. GE (NYSE: GE) works on
things that matter - great people and technologies taking on tough
challenges. From medical imaging, software & IT, patient monitoring and
diagnostics to drug discovery, biopharmaceutical manufacturing
technologies and performance improvement solutions, GE Healthcare helps
medical professionals deliver great healthcare to their patients.
GE HealthcareScott Lerman609-514-6346 (office)609-937-9253
Source: GE Healthcare